AstraZeneca
AstraZeneca Appoints Iskra Reic as New International Operations Lead Following Investigation into China Executive
AstraZeneca, Iskra Reic, Leon Wang, China investigation, international operations lead
AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback
AstraZeneca, Truqap, prostate cancer, Phase III trial, PTEN-deficient metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT).
AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion
AstraZeneca, Truqap, prostate cancer, Phase 3 trial, CAPItello-281, PTEN-deficient, metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT)
AstraZeneca Addresses Safety Concerns Over Andexxa, Discontinues Opioid Use Disorder Drug
AstraZeneca, Andexxa, FDA, Safety Concerns, Anticoagulation Reversal, Opioid Use Disorder, AZD4041
AstraZeneca Halts Development of Opioid Use Disorder Drug Due to Antifungal Interaction
AstraZeneca, Opioid Use Disorder, Drug Development, Antifungal Interaction, Clinical Trials
FDA Panel Raises Safety Concerns Over AstraZeneca’s Anticoagulant Reversal Drug Andexxa
AstraZeneca, Andexxa, FDA panel, anticoagulant reversal drug, safety concerns, full approval
FDA Raises Safety Concerns Over AstraZeneca’s Andexxa Ahead of Advisory Committee Meeting
AstraZeneca, Andexxa, FDA, safety concerns, bleeding reversal agent, advisory committee meeting
NICE Rejects Enhertu for NHS Use Due to Pricing Stalemate with AstraZeneca and Daiichi Sankyo
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, breast cancer, pricing stalemate, NHS, England
AstraZeneca and Amgen’s Tezspire Shows Efficacy in Phase 3 Trial for Chronic Rhinosinusitis with Nasal Polyps, Despite Regulatory Risk Concerns
Tezspire, AstraZeneca, Amgen, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Phase 3 Trial, Regulatory Risk
Tezspire Shows Promise in Treating Chronic Rhinosinusitis with Nasal Polyps
Tezspire, chronic rhinosinusitis with nasal polyps (CRSwNP), AstraZeneca, Amgen, WAYPOINT trial, TSLP inhibitor, nasal congestion, nasal polyps.